Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 4/2014

01.12.2014 | Treatment as Prevention (RM Granich, Section Editor)

Modeling the Implementation of Universal Coverage for HIV Treatment as Prevention and its Impact on the HIV Epidemic

verfasst von: Roger Ying, Ruanne V. Barnabas, Brian G. Williams

Erschienen in: Current HIV/AIDS Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The Joint United Nations Programme on HIV/AIDS (UNAIDS) recently updated its global targets for antiretroviral therapy (ART) coverage for HIV-positive persons under which 90 % of HIV-positive people are tested, 90 % of those are on ART, and 90 % of those achieve viral suppression. Treatment policy is moving toward treating all HIV-infected persons regardless of CD4 cell count—otherwise known as treatment as prevention—in order to realize the full therapeutic and preventive benefits of ART. Mathematical models have played an important role in guiding the development of these policies by projecting long-term health impacts and cost-effectiveness. To guide future policy, new mathematical models must consider the barriers patients face in receiving and taking ART. Here, we describe the HIV care cascade and ART delivery supply chain to examine how mathematical modeling can provide insight into cost-effective strategies for scaling-up ART coverage in sub-Saharan Africa and help achieve universal ART coverage.
Literatur
1.
Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879–84.PubMedCentralPubMedCrossRef
2.•
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. This paper describes the results of the first randomized study of early ART treatment for preventing HIV transmission (HPTN 052) which demonstrated a 96% reduction in the risk of HIV transmission with early ART provision.PubMedCentralPubMedCrossRef
3.
Delva W, Eaton JW, Meng F, Fraser C, White RG, Vickerman P, et al. HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med. 2012;9:e1001258.PubMedCentralPubMedCrossRef
4.
Sidibé M, Zuniga JM, Montaner J. Leveraging HIV treatment to end AIDS, stop new HIV infections, and avoid the cost of inaction. Clin Infect Dis. 2014;59 Suppl 1:S3–6.PubMedCentralPubMedCrossRef
5.
Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966–71.PubMedCentralPubMedCrossRef
6.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.PubMedCentralPubMedCrossRef
7.
Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE. 2010;5:e11068.PubMedCentralPubMedCrossRef
8.••
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. This mathematical modeling study is the first to suggest that HIV treatment as prevention can eliminate HIV transmission.PubMedCrossRef
9.
Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27:447–58.PubMedCrossRef
10.
Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.PubMedCentralPubMedCrossRef
11.
Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment—a study protocol for a cluster randomised trial. Trials. 2014;15:57.PubMedCentralPubMedCrossRef
12.
Easterbrook PJ, Doherty MC, Perriëns JH, Barcarolo JL, Hirnschall GO. The role of mathematical modelling in the development of recommendations in the 2013 WHO consolidated antiretroviral therapy guidelines. AIDS. 2014;28 Suppl 1:S85–92.PubMedCrossRef
13.
Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med. 2012;9:e1001231.PubMedCentralPubMedCrossRef
14.
Kilmarx PH, Mutasa-Apollo T. Patching a leaky pipe: the cascade of HIV care. Curr Opin HIV AIDS. 2013;8:59–64.PubMed
15.
16.
van Rooyen H, Barnabas RV, Baeten JM, Phakathi Z, Joseph P, Krows M, et al. High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2013;64:e1–8.PubMedCentralPubMedCrossRef
17.
Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001351.PubMedCentralPubMedCrossRef
18.
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, et al. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS ONE. 2014;9:e84317.PubMedCentralPubMedCrossRef
19.•
Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10:e1001496. This review and meta-analysis summarizes various community-based modalities for increasing HIV testing and linkage to care.PubMedCentralPubMedCrossRef
20.
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, et al. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS ONE. 2012;7:e43400.PubMedCentralPubMedCrossRef
21.
Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet. 2013;382:1515–24.PubMedCrossRef
22.
Lima VD, Thirumurthy H, Kahn JG, Saavedra J, Cárceres CF, Whiteside A. Modeling scenarios for the end of AIDS. Clin Infect Dis. 2014;59 Suppl 1:S16–20.PubMedCrossRef
23.
El-Sadr WM, Philip NM, Justman J. Letting HIV transform academia—embracing implementation science. N Engl J Med. 2014;370:1679–81.PubMedCrossRef
24.
Young B, Zuniga JM, Montaner J, Mayer KH. Controlling the HIV epidemic with antiretrovirals: moving from consensus to implementation. Clin Infect Dis. 2014;59 Suppl 1:S1–2.PubMedCrossRef
25.
Wilson D, Fraser N. Who pays and why? Costs, effectiveness, and feasibility of HIV treatment as prevention. Clin Infect Dis. 2014;59 Suppl 1:S28–31.PubMedCrossRef
26.
McNairy ML, El-Sadr WM. A paradigm shift: focus on the HIV prevention continuum. Clin Infect Dis. 2014;59 Suppl 1:S12–5.PubMedCrossRef
27.
Nachega JB, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the Achilles’ heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59 Suppl 1:S21–7.PubMedCrossRef
28.
Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE. 2012;7:e30216.PubMedCentralPubMedCrossRef
29.
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369:1715–25.PubMedCentralPubMedCrossRef
30.
Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS ONE. 2014;9:e84511.PubMedCentralPubMedCrossRef
31.
Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9:446–69.PubMedCentralPubMedCrossRef
32.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2013;2:23–34.PubMedCentralPubMedCrossRef
33.
Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–56.PubMedCrossRef
34.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.PubMedCentralPubMedCrossRef
35.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.PubMedCentralPubMedCrossRef
36.
Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, et al. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS ONE. 2013;8:e54575.PubMedCentralPubMedCrossRef
37.
Kates J, Wexler A, Lief E. Financing the response to HIV in low- and middle-income countries: international assistance from donor governments in 2013. Kaiser Family Foundation; 2014.
38.
Facility-based unit costing for antiretroviral treatment in five Sub-Saharan African countries. The Clinton Health Access Initiative; 2011.
39.
National AIDS and STI Control Programme (NASCOP), Kenya. Kenya AIDS indicator survey 2012: final report. Nairobi: NASCOP; 2014.
40.
Shisana O, Rehle T, Simbayi L, Parker W, Jooste S, van Wyk VP, et al. South African national HIV prevalence, incidence, behavior and communication survey 2008: a turning tide among teenagers? Cape Town, South Africa; 2008.
41.
Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Zungu N, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town; 2014.
42.
Lugada E, Millar D, Haskew J, Grabowsky M, Garg N, Vestergaard M, et al. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS ONE. 2010;5:e12435.PubMedCentralPubMedCrossRef
43.
Lazarus JV, Safreed-Harmon K, Nicholson J, Jaffar S. Health service delivery models for the provision of antiretroviral therapy in sub-Saharan Africa: a systematic review. Trop Med Int Health. 2014.
44.
Rosenberg NE, Pettifor AE, De Bruyn G, Westreich D, Delany-Moretlwe S, Behets F, et al. HIV testing and counseling leads to immediate consistent condom use among South African stable HIV-discordant couples. J Acquir Immune Defic Syndr. 2013;62:226–33.PubMedCentralPubMedCrossRef
45.
Montgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women’s acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011;15:959–69.PubMedCentralPubMedCrossRef
46.
Barnabas R, Ying R, van Rooyen H, Murnane P, Hughes J, Baeten J, et al. Use of HIV viral-load suppression to estimate the effect of community-wide home-based HIV counselling and testing and linkage to antiretroviral therapy on HIV incidence in South Africa: a mathematical modelling analysis. Lancet. 2013;382(Supplement 2):S6.CrossRef
47.
Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24:729–35.PubMedCentralPubMedCrossRef
48.•
Birger RB, Hallett TB, Sinha A, Grenfell BT, Hodder SL. Modeling the impact of interventions along the HIV continuum of care in Newark, New Jersey. Clin Infect Dis. 2013. This mathematical model simulates the HIV care cascade in Newark, New Jersey, and is one of the first models to critically assess specific steps in the care cascade.
49.
Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS. 2011;25:2177–81.PubMedCentralPubMedCrossRef
50.
Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, et al. Who starts antiretroviral therapy in Durban, South Africa?… not everyone who should. AIDS. 2010;24 Suppl 1:S37–44.PubMedCentralPubMedCrossRef
51.
Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15 Suppl 1:1–15.PubMedCentralPubMedCrossRef
52.
Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405–11.PubMedCentralPubMedCrossRef
53.
Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bull World Health Organ. 2007;85:550–4.PubMedCentralPubMedCrossRef
54.
Rosen S, Ketlhapile M. Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health. 2010;15 Suppl 1:98–104.PubMedCentralPubMedCrossRef
55.
Rich ML, Miller AC, Niyigena P, Franke MF, Niyonzima JB, Socci A, et al. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr. 2012;59:e35–42.PubMedCrossRef
56.
Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS ONE. 2014;9:e87872.PubMedCentralPubMedCrossRef
57.
Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14:40–9.PubMedCentralPubMedCrossRef
58.
Estill J, Tweya H, Egger M, Wandeler G, Feldacker C, Johnson LF, et al. Tracing of patients lost to follow-up and HIV transmission: mathematical modeling study based on 2 large ART programs in Malawi. J Acquir Immune Defic Syndr. 2014;65:e179–86.PubMedCrossRef
59.
Klein DJ, Bershteyn A, Eckhoff PA. Dropout and re-enrollment: implications for epidemiological projections of treatment programs. AIDS. 2014;28 Suppl 1:S47–59.PubMedCrossRef
60.
Hoffmann CJ, Lewis JJ, Dowdy DW, Fielding KL, Grant AD, Martinson NA, et al. Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr. 2013;63:105–11.PubMedCentralPubMedCrossRef
61.
Hallett TB, Eaton JW. A side door into care cascade for HIV-infected patients? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S228–32.PubMedCrossRef
62.
UNAIDS/WHO. Global report: UNAIDS report on the global AIDS epidemic, 2013. Joint United Nations Programme on HIV/AIDS; 2013.
63.
Tolle MA, Phelps BR, Desmond C, Sugandhi N, Omeogu C, Jamieson D, et al. Delivering pediatric HIV care in resource-limited settings: cost considerations in an expanded response. AIDS. 2013;27 Suppl 2:S179–86.PubMedCrossRef
64.
Okoronkwo I, Okeke U, Chinweuba A, Iheanacho P. Nonadherence factors and sociodemographic characteristics of HIV-infected adults receiving antiretroviral therapy in Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. ISRN AIDS. 2013;2013:843794.PubMedCentralPubMedCrossRef
65.•
Kraiselburd S, Yadav P. Supply chains and global health: an imperative for bringing operations management scholarship into action, production and operations management. Production and operations management; 2013. pp. 377–381. This paper discusses the importance of supply chains in delivering critical medications in global health, as well as current supply chain weaknesses.
66.
Ambitious treatment targets: writing the final chapter of the AIDS epidemic. Geneva: UNAIDS; 2014.
67.
Fernandez M. Improving access to critical medicines: the last mile. HIV treatment as prevention workshop. Vancouver; 2014.
68.
Trochim WM, Cabrera DA, Milstein B, Gallagher RS, Leischow SJ. Practical challenges of systems thinking and modeling in public health. Am J Public Health. 2006;96:538–46.PubMedCentralPubMedCrossRef
69.
70.
Bill & Melinda Gates Foundation. Oral PrEP in South Africa. Bottom-up cost model.
71.
Rosen JE, Bancroft E, Hasselback L, Levin C, Mvundura M, Tien M. Last mile costs of public health supply chains in developing countries: recommendations for inclusion in the United Nations OneHealth Model. Arlington: USAID | DELIVER PROJECT, Task Order 4; 2012.
72.••
Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9:e1001247. The authors explain the importance of including cost functions into mathematical models to provide more accurate estimates of the programmatic costs of ART provision.PubMedCentralPubMedCrossRef
73.
Marseille E, Dandona L, Marshall N, Gaist P, Bautista-Arredondo S, Rollins B, et al. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res. 2007;7:108.PubMedCentralPubMedCrossRef
74.
Guinness L, Kumaranayake L, Rajaraman B, Sankaranarayanan G, Vannela G, Raghupathi P, et al. Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ. 2005;83:747–55.PubMedCentralPubMed
75.
76.
Brown ST, Schreiber B, Cakouros BE, Wateska AR, Dicko HM, Connor DL, et al. The benefits of redesigning Benin’s vaccine supply chain. Vaccine. 2014;32:4097–103.PubMedCrossRef
77.
Assi TM, Brown ST, Kone S, Norman BA, Djibo A, Connor DL, et al. Removing the regional level from the Niger vaccine supply chain. Vaccine. 2013;31:2828–34.PubMedCentralPubMedCrossRef
78.
Futures Institute. OneHealthTool. 2011.
79.
80.
Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382:1898–955.PubMedCrossRef
81.
Ekici A, Keskinocak P, Swann JL. Pandemic influenza response. Winter simulation conference. Miami, FL; 2008.
82.
Mvundura M, Kien VD, Nga NT, Robertson J, Cuong NV, Tung HT, et al. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam’s Expanded Program on Immunization. Vaccine. 2014;32:834–8.PubMedCrossRef
83.
McChord J, Tien M, Sarley D. Guide to public health supply chain costing: a basic methodology. Arlington: USAID | DELIVER PROJECT, Task Order 4; 2013.
84.
Nkengasong JN, Nsubuga P, Nwanyanwu O, Gershy-Damet GM, Roscigno G, Bulterys M, et al. Laboratory systems and services are critical in global health: time to end the neglect? Am J Clin Pathol. 2010;134:368–73.PubMedCrossRef
85.
Alemnji G, Fonjungo P, Van Der Pol B, Peter T, Kantor R, Nkengasong J. The centrality of laboratory services in the HIV treatment and prevention cascade: the need for effective linkages and referrals in resource-limited settings. AIDS Patient Care STDS. 2014;28:268–73.PubMedCrossRef
86.
Upfill-Brown AM, Lyons HM, Pate MA, Shuaib F, Baig S, Hu H, et al. Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria. BMC Med. 2014;12:92.PubMedCentralPubMedCrossRef
87.
Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet. 2014;384:249–56.PubMedCrossRef
88.
Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13:349–61.PubMedCrossRef
89.
Reiser H. Making new drugs available to all. HIV treatment as prevention workshop. Vancouver, Canada; 2014.
90.
Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions? Soc Sci Med. 2012;75:1572–80.PubMedCrossRef
91.
Levine R, Pickett J, Sekhri N, Yadav P. Demand forecasting for essential medical technologies. Am J Law Med. 2008;34:225–55.PubMed
Metadaten
Titel
Modeling the Implementation of Universal Coverage for HIV Treatment as Prevention and its Impact on the HIV Epidemic
verfasst von
Roger Ying
Ruanne V. Barnabas
Brian G. Williams
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 4/2014
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0232-x

Weitere Artikel der Ausgabe 4/2014

Current HIV/AIDS Reports 4/2014 Zur Ausgabe

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Palliative HIV Care: Opportunities for Biomedical and Behavioral Change

Treatment as Prevention (RM Granich, Section Editor)

Treatment as Prevention—Where Next?

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Review of Recent Behavioral Interventions Targeting Older Adults Living with HIV/AIDS

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Optimizing ART Adherence: Update for HIV Treatment and Prevention

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Contraceptive Methods and Risk of HIV Acquisition or Female-to-Male Transmission

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise